GNRH1 and breast carcinoma: Mingqiang et al. developed cisplatin-loaded LHRH-modified dextran NPs (Dex-SA-CDDP-LHRH), which could specifically target LHRH receptors overexpressed on the surface of 4T1 breast cancer cells [125].